148 related articles for article (PubMed ID: 33032396)
1. Thrombo-prophylaxis prevents thrombotic events in home-managed COVID patients. A registry study.
Belcaro G; Corsi M; Agus GB; Cesarone MR; Cornelli U; Cotellese R; Feragalli B; Hu S
Minerva Med; 2020 Aug; 111(4):366-368. PubMed ID: 33032396
[No Abstract] [Full Text] [Related]
2. First case report of a successfully managed severe COVID-19 infection in Malawi.
Banda NP; Hara W; Cocker D; Musasa S; Burke RM; Brown C; Nyasulu V; Mandalo J; Tembo D; Kachingwe M; Cornick J; Jambo K; Morton B
Malawi Med J; 2020 Dec; 32(4):226-228. PubMed ID: 34457208
[No Abstract] [Full Text] [Related]
3. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection.
Trunfio M; Salvador E; Cabodi D; Marinaro L; Alcantarini C; Gaviraghi A; Trentalange A; Lipani F; Sciascia S; Roccatello D; Bonora S; Di Perri G; Calcagno A;
Thromb Res; 2020 Dec; 196():432-434. PubMed ID: 33049598
[No Abstract] [Full Text] [Related]
4. Secondary prophylaxis with low molecular weight heparin: the dose?
Horne MK
Thromb Haemost; 2001 Oct; 86(4):1129. PubMed ID: 11686343
[No Abstract] [Full Text] [Related]
5. Primary thromboprophylaxis in a patient with type 3 von Willebrand disease and severe COVID-19 infection.
Vagrecha A; Stanco J; Majeed S; Kouides P; Acharya SS
Haemophilia; 2021 Jul; 27(4):e517-e519. PubMed ID: 33427345
[No Abstract] [Full Text] [Related]
6. Venovenous Extracorporeal Membrane Oxygenation With Prophylactic Subcutaneous Anticoagulation Only: An Observational Study in More Than 60 Patients.
Krueger K; Schmutz A; Zieger B; Kalbhenn J
Artif Organs; 2017 Feb; 41(2):186-192. PubMed ID: 27256966
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of D-dimer, Weight, and Renal Function-Adjusted Thromboprophylaxis in Patients with Coronavirus Disease 2019 (COVID-19).
Arachchillage DRJ; Shi C; Saliu D; Kozman P; Mi E; Buti N; Kashef E; Copley SJ; Gomez C; Leonard R; Aziz R; Shlebak AA; Laffan M
Semin Thromb Hemost; 2021 Jun; 47(4):436-441. PubMed ID: 33482676
[No Abstract] [Full Text] [Related]
8. The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination.
Perhoniemi V; Vuorinen J; Myllynen P; Kivioja A; Lindevall K
Ann Chir Gynaecol; 1996; 85(4):359-63. PubMed ID: 9014067
[TBL] [Abstract][Full Text] [Related]
9. [Anticoagulation with low molecular weight heparins within the framework of cardioversion for atrial fibrillation].
Tebbe U
Dtsch Med Wochenschr; 2007 Sep; 132(39):2033-6. PubMed ID: 17882745
[No Abstract] [Full Text] [Related]
10. Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization.
D'Ardes D; Carrarini C; Russo M; Dono F; Speranza R; Digiovanni A; Martinotti G; Di Iorio A; Onofrj M; Cipollone F; Bonanni L
Neurol Sci; 2021 Apr; 42(4):1527-1530. PubMed ID: 33185785
[TBL] [Abstract][Full Text] [Related]
11. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
12. Recurrent miscarriages: caution regarding development of clinical trials using low molecular weight heparin and pregnancy.
Misra D; Aledort L
Am J Hematol; 2011 Feb; 86(2):235. PubMed ID: 21264918
[No Abstract] [Full Text] [Related]
13. [Efficacy and safety of low molecular weight heparin in the treatment of pulmonary thromboembolism].
Cereza G; Danés I
Med Clin (Barc); 1999 Jun; 113(3):115-6. PubMed ID: 10464747
[No Abstract] [Full Text] [Related]
14. Low molecular weight heparins in acute coronary syndrome.
Creekmore F
S D J Med; 2000 Jan; 53(1):21-3. PubMed ID: 10652862
[No Abstract] [Full Text] [Related]
15. Surviving Covid-19 with Heparin?
Ten Cate H
N Engl J Med; 2021 Aug; 385(9):845-846. PubMed ID: 34347948
[No Abstract] [Full Text] [Related]
16. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168
[TBL] [Abstract][Full Text] [Related]
17. [Thromboembolisms endanger the internist patients, too: who needs heparin].
Bischoff A
MMW Fortschr Med; 2006 Mar; 148(11):21-2. PubMed ID: 16612959
[No Abstract] [Full Text] [Related]
18. [Low-molecular weight heparin in the treatment of pregnant women with high thrombotic risk].
Todorova K; Mazneĭkova V; Ivanov S
Akush Ginekol (Sofiia); 2004; 43(4):46-52. PubMed ID: 15318544
[No Abstract] [Full Text] [Related]
19. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis with low-molecular-weight heparin reduces thrombotic events and allows continuation of asparaginase containing regimens during intensification phase.
Sibai H; Atenafu EG; Seki JT
Br J Haematol; 2022 Apr; 197(2):e32-e34. PubMed ID: 34994976
[No Abstract] [Full Text] [Related]
[Next] [New Search]
